Showing 1240 results
-
Press release /Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community…
-
Press release /EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
-
Press release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
-
Press release /Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
-
Press release /New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
-
Press release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
-
Press release /Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as…
-
Press release /Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions…
-
Press release /Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des…
-
Press release /PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…